International Journal of Clinical Pharmacy

, Volume 39, Issue 4, pp 783–790 | Cite as

Counselling pregnant women at the crossroads of Europe and Asia: effect of Teratology Information Service in Turkey

  • Yusuf Cem KaplanEmail author
  • Barış Karadaş
  • Gözde Küçüksolak
  • Bartu Ediz
  • Ömer Demir
  • Kaan Sozmen
  • Hedvig Nordeng
Research Article


Background Previous studies from western countries demonstrated the effectiveness of Teratology Information Service (TIS) counselling in reducing the teratogenic risk perception of pregnant women. Objective To assess whether TIS counselling would be effective in reducing the teratogenic risk perception of the Turkish pregnant women. Setting A TIS (Terafar) operating in a university hospital in Turkey. Methods A cross-sectional survey study. Pregnant women with non-teratogenic medication exposures were asked to assign scores on visual analogue scales (VAS) in response to the questions aiming to measure their teratogenic risk perception. The mean score before and after counselling were compared and the associations with maternal socio-demographic characteristics were analysed using SPSS (Version 20.0). Main outcome measures The differences in the mean scores of the perception regarding the baseline risk of pregnancy, own teratogenic risk and the likelihood of termination of pregnancy before and after counselling and their possible associations with maternal socio-demographic characteristics. Results 102 pregnant women participated in the study. The counselling significantly reduced the mean own teratogenic risk perception score and the mean score for the likelihood of termination of pregnancy whereas the mean baseline risk perception score was not significantly changed. Pregnancy week <8 and the exposed number of active ingredients <3 were significantly associated with the difference in the mean score for the likelihood of termination of pregnancy. Conclusions TIS counselling lowers the teratogenic risk perception of Turkish pregnant women and increases their likelihood to continue the pregnancy as it does in the western countries.


Medications Patient perception Pregnancy Risk perception Teratogenic risk Teratology Information Service Turkey 



We thank all the women who participated in the study.


None reported.

Conflicts of interest

The authors declare no conflict of interest.


  1. 1.
    Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205:51.e1-8.CrossRefPubMedGoogle Scholar
  2. 2.
    Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mårdby AC, Moretti ME, et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open. 2014;4:e004365.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol. 2002;100:465–73.PubMedGoogle Scholar
  4. 4.
    Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C. 2011;157:175–82.CrossRefGoogle Scholar
  5. 5.
    Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84:478–85.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160:1190–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J Obstet Gynecol Reprod Biol. 2001;95:127–31.CrossRefPubMedGoogle Scholar
  8. 8.
    Nordeng H, Ystrøm E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66:207–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Petersen I, McCrea RL, Lupattelli A, Nordeng H. Women’s perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey. BMJ Open. 2015;5:e007390.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Schaefer C. Drug safety in pregnancy: utopia or achievable prospect? Risk information, risk research and advocacy in teratology information services. Congenit Anom Kyoto. 2011;51:6–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Leen-Mitchell M, Martinez L, Gallegos S, Robertson J, Carey JC. Mini-review: history of organized teratology information services in North America. Birth Defect Res A. 2000;61:314–7.Google Scholar
  12. 12.
    Peters P, Miller RK, Schaefer C. General commentary on drug therapy and drug risks in pregnancy. In: Schaefer C, Peters P, Miller RK, editors. Drugs during pregnancy and lactation: treatment options and risk assessment. Academic Press: Waltham; 2014 (Kindle Location 1058).Google Scholar
  13. 13.
    Conover EA, Polifka JE. The art and science of teratogen risk communication. Am J Med Genet C Semin Med Genet. 2011;157:227–33.CrossRefGoogle Scholar
  14. 14.
    Koren G, Gladstone D, Robeson C, Robieux I. The perception of teratogenic risk of cocaine. Birth Defect Res A. 1992;46:567–71.Google Scholar
  15. 15.
    Mazzotta P, Magee LA, Maltepe C, Lifshitz A, Navioz Y, Koren G. The perception of teratogenic risk by women with nausea and vomiting of pregnancy. Reprod Toxicol. 1999;13:313–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J Psychiatry Neurosci. 2001;26:44–8.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Women Ment Health. 2005;8:214–20.CrossRefGoogle Scholar
  18. 18.
    Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56:761–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Turkish Statistical Institute Website. Main Statistics, Population and Demography,Vital Statistics. 2014. Accessed 5 March 2015.
  20. 20.
    Basara BB, Guler C, Yentur GK (Eds.) Prevention of diseases and protection of health. Annual health statistics report of Turkish Ministry of Health. Ankara: Sentez Matbaacılık ve Yayıncılık; 2013. p. 65.Google Scholar
  21. 21.
    Alsulaiman A, Hewison J, Abu-Amero KK, Ahmed S, Green JM, Hirst J. Attitudes to prenatal diagnosis and termination of pregnancy for 30 conditions among women in Saudi Arabia and the UK. Prenat Diagn. 2012;32:1109–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Larsson M, Aneblom G, Odlind V, Tydén T. Reasons for pregnancy termination, contraceptive habits and contraceptive failure among Swedish women requesting an early pregnancy termination. Acta Obstet Gynecol Scan. 2002;81:64–71.CrossRefGoogle Scholar
  23. 23.
    Bankole A, Singh S. Couples’ fertility and contraceptive decision-making in developing countries: hearing the man’s voice. Int Fam Plan Perspect. 1998;24:15–24.CrossRefGoogle Scholar
  24. 24.
    El-Zanaty FH, Sayed HA, Zaky HH, Way AA. Egypt demographic and health survey 1992. Natl Popul Counc. 1993;26:317.Google Scholar
  25. 25.
    Törnbom M, Ingelhammar E, Lilja H, Möller A, Svanberg B. Evaluation of stated motives for legal abortion. J Psychosom Obstet Gynaecol. 1994;15:27–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Kirkman M, Rowe H, Hardiman A, Mallett S, Rosenthal D. Reasons women give for abortion: a review of the literature. Arch Women Ment Health. 2009;12:365–78.CrossRefGoogle Scholar
  27. 27.
  28. 28.
    Koren G. Maternal depression and perception of teratogenic risk. Isr J Psychiatry Relat. 2014;51:106–8.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Yusuf Cem Kaplan
    • 1
    • 2
    Email author
  • Barış Karadaş
    • 1
    • 2
  • Gözde Küçüksolak
    • 1
  • Bartu Ediz
    • 1
  • Ömer Demir
    • 3
  • Kaan Sozmen
    • 4
  • Hedvig Nordeng
    • 5
  1. 1.Terafar - Izmir Katip Celebi University Teratology InformationTraining and Research CenterIzmirTurkey
  2. 2.Izmir Katip Celebi University School of Medicine Department of PharmacologyIzmirTurkey
  3. 3.Cordoba Saglik ve Danismanlik Ltd. Sti.IstanbulTurkey
  4. 4.Izmir Katip Celebi University School of Medicine Department of Public HealthIzmirTurkey
  5. 5.Pharmacoepidemiology and Drug Safety Research Group, School of Pharmacy, Faculty of Mathematics and Natural SciencesUniversity of OsloOsloNorway

Personalised recommendations